Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.34 |
| ▸ | POLB | P06746 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | HPGD | P15428 | 1/20 | 0.33 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.33 |
| ▸ | HTT | P42858 | 2/20 | 0.33 |
| ▸ | DAO | P14920 | 1/20 | 0.33 |
| ▸ | PLAU | P00749 | 1/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | GLA | P06280 | 1/20 | 0.33 |
| ▸ | TSHR | P16473 | 1/20 | 0.33 |
| ▸ | ATM | Q13315 | 1/20 | 0.31 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.30 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2912781 | 0.80 | ALDH1A1 (0.46) | ALDH1A1KDM4EPOLBKMT2AHPGD | |
| SCHEMBL11192626 | 0.80 | CCR1 (0.34) | ALDH1A1KDM4EPOLBKMT2ALMNA | |
| SCHEMBL3831428 | 0.80 | HTT (0.37) | KDM4EKMT2ALMNAHPGDHTT | |
| SCHEMBL17508469 | 0.77 | PLAU (0.36) | ALDH1A1KDM4EPOLBKMT2AHTT | |
| SCHEMBL677211 | 0.74 | RECQL (0.41) | ALDH1A1KDM4EPOLBKMT2ALMNA | |
| SCHEMBL30885009 | 0.69 | DAO (0.35) | DAOPLAU | |
| SCHEMBL3830239 | 0.69 | ALDH1A1 (0.43) | ALDH1A1KDM4EKMT2AHPGDL3MBTL1 | |
| SCHEMBL2981053 | 0.69 | CSNK1A1 (0.39) | ALDH1A1KDM4EKMT2AHPGDHTT | |
| SCHEMBL20270466 | 0.68 | HTT (0.55) | ALDH1A1KDM4EKMT2ALMNAHPGD | |
| SCHEMBL18283565 | 0.68 | POLB (0.48) | ALDH1A1KDM4EPOLBKMT2AHTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1999110-B1 | PROCESS FOR PREPARING l-HALO-2,7-NAPHTHYRIDINYL DERIVATIVES | UCB PHARMA SA (BE) | 2009-09-16 | — | — | EP | disclosed |
| US-20090221828-A1 | Process for Preparing 1-Halo-2,7-Naphthyridinyl Derivatives | UCB PHARMA, S.A. (BE) | 2009-09-03 | — | — | US | disclosed |
| EP-1999110-A2 | PROCESS FOR PREPARING l-HALO-2,7-NAPHTHYRIDINYL DERIVATIVES | UCB Pharma, S.A. (BE) | 2008-12-10 | — | — | EP | disclosed |
| WO-2007107345-A2 | PROCESS FOR PREPARING l-HALO-2,7-NAPHTHYRIDINYL DERIVATIVES | UCB PHARMA, S.A. (BE) | 2007-09-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090221828-A1 | Process for Preparing 1-Halo-2,7-Naphthyridinyl Derivatives | NPM1, XPO4, BRD7 | ALDH1A1 2507/4885KDM4E 1447/4885POLB 490/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.